Sanofi-Aventis Sees A Bright Future In Boston-CambridgeSanofi CEO Chris Viehbacher says research departments have been consolidated here to be near universities.
It's A Done Deal For GenzymeAfter nine months of denials, rejection, bickering and finally, discussion, French pharmaceutical company Sanofi-Aventis of Paris has signed a deal to buy Genzyme of Cambridge for $20.1 billion plus other milestone payments in the future.
Genzyme Sold To Sanofi-Aventis In $20 Billion DealCambridge-based biotechnology company Genzyme is being bought by French drug maker Sanofi-Aventis for $20.1 billion, ending months of corporate haggling.
Genzyme Rejects Latest Sanofi OfferSanofi-Aventis extended its unsolicited $18.5 billion takeover offer for Cambridge biotech company Genzyme Corp. Monday.
Talk of possible Genzyme sale heating up